Canntab Brings Pharma Standards to Medical Cannabis
May 31st, 2018
Exclusive, News, Top Story
According to Arcview Market Research the North American cannabis industry is expected to grow more than three-fold from $6.57 billion in 2016 to $20.2 billion by 2021. The legalization of adult-use cannabis by the government of Canada will open the door to a much wider market in Canada, where legalization is currently anticipated for the summer of 2018. There are signs that U.S. lawmakers are ready to further legitimize medical cannabis by potentially removing marijuana from the list of Schedule I Controlled Substances.
As with any rapidly expanding market, there have been many growing pains along the way. Canadian licensed producers have been plagued with recalls for contaminated products due to the lack of testing standards, while inaccurate labeling has hurt consumers’ trust in the regulated medical cannabis space. Many medical cannabis companies and doctors also struggle with dosing issues given the unique nature of cannabis and the lack of robust clinical trial data.
CannTab Therapeutics Inc. (TSX: PILL) aims to deal with these issues by making medical cannabis more reliable with its proprietary, patent-pending, extended-release tablets that offer a reliable and uniform dosage over several hours. By making medical cannabis more like traditional pharmaceuticals, these products should be more readily prescribed by doctors than the smoking of cannabis flower.
A Lack of Standards
Cannabis bioavailability is a significant issue facing the medical community. In a 2009 study, researchers found that cannabinoid bioavailability ranged from two to 56 percent for inhaled cannabis smoke and from four to 20 percent for orally consumed cannabis products. These wide ranges make it difficult for physicians to anticipate how cannabis will affect a patient, which makes them less likely to prescribe cannabis-based medications.
The reality is that cannabis affects different people in different ways due to its nature. For one, cannabis contains hundreds of cannabinoids that interact in ways that scientists are only starting to understand. The metabolism of cannabinoids also depends on an individual’s body type since it’s a fat-soluble and subject to first-pass liver metabolism. And finally, regular users may build up a tolerance and require higher dosing than casual or new users.
Many companies have started to develop cannabinoid delivery mechanisms designed to improve bioavailability, but it’s a challenging task that requires extensive research and development. In addition, many of these delivery mechanisms may be unfamiliar to patients that are accustomed to taking pharmaceutical drugs in pill form. The most promising companies are those that are closely adhering to pharmaceutical standards.
Canntab’s Unique Solutions
Canntab Therapeutics aims to develop advanced pharmaceutical-grade cannabis formulations. Using its in-house technology, the company delivers standardized medical cannabis extract from selective strains in a variety of extended-release/sustained release pharmaceutical dosages for therapeutic use. As the company likes to say, it puts the “medical” into “medical cannabis” by bringing pharmaceutical standards to the industry.
The company’s proprietary, patent-pending Canntab XR Tablets provide an extended release and uniform dosing of cannabis over an extended number of hours. Doctors or patients can access a wide range of THC/CBD variations to effectively manage any ailment, while taking advantage of the discreet tablet format that easily fits into any patient’s lifestyle. These tablets are also highly reliable and made to pharmaceutical-grade standards.
In late-2017, the company signed a licensing deal with Emblem Corp. (TSX-V: EMC), a Canadian licensed producer of medical cannabis, to market and develop products in Canada, and closed a joint venture deal with Queensland Bauxite to make its products available in Australia and Asia. Recently, Health Canada approved R&D activities for Canntab’s oral sustained release formulations of cannabinoids, which paves the way for these new products.
“We are thrilled that Health Canada has approved the research and development phase of our partnership with Canntab,” said Emblem President and CEO Nick Dean in the press release announcing the approval. “The introduction of Canntab’s sustained release formulation presents a significant growth opportunity for Emblem that is expected to begin in 2019.”
In addition to that licensing deal, the company announced a joint venture with Queensland Bauxite (ASX: QBL) to develop and market its patented tablets. The new venture will compete with MMJ Phytotech (ASX: MMJ), which is the only company that’s currently importing a cannabis-containing pill in partnership with the Swiss drugmaker, Satipharm. Queensland Bauxite is confident that the standardized dosing will convince doctors and regulators to support the product as a way to prescribe measurable doses of cannabis.
Management is also working to close a deal to co-locate with FV Pharma to produce and distribute its products in Canada and around the world.
CannTab Therapeutics Inc. (CSE: PILL) represents a compelling investment opportunity within the burgeoning cannabis industry. By addressing key issues with bioavailability and dosing, the company’s products should appeal to traditional doctors and patients looking for reliable solutions to meet their medical needs. Recreational users will be able to benefit from a consistent experience as well.
For more information, visit the Company’s Website at: Canntab Therapeutics Inc.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.